Ono Pharmaceutical Co. Ltd (ON4) - Net Assets
Based on the latest financial reports, Ono Pharmaceutical Co. Ltd (ON4) has net assets worth €788.20 Billion EUR as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.06 Trillion) and total liabilities (€275.84 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €788.20 Billion |
| % of Total Assets | 74.08% |
| Annual Growth Rate | 5.76% |
| 5-Year Change | 22.93% |
| 10-Year Change | N/A |
| Growth Volatility | 5.0 |
Ono Pharmaceutical Co. Ltd - Net Assets Trend (2016–2025)
This chart illustrates how Ono Pharmaceutical Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ono Pharmaceutical Co. Ltd (2016–2025)
The table below shows the annual net assets of Ono Pharmaceutical Co. Ltd from 2016 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | €788.20 Billion | -1.30% |
| 2024-03-31 | €798.61 Billion | +6.79% |
| 2023-03-31 | €747.81 Billion | +13.02% |
| 2022-03-31 | €661.67 Billion | +3.20% |
| 2021-03-31 | €641.16 Billion | +12.88% |
| 2020-03-31 | €568.02 Billion | +0.94% |
| 2019-03-31 | €562.74 Billion | +6.25% |
| 2018-03-31 | €529.62 Billion | +1.03% |
| 2017-03-31 | €524.21 Billion | +10.07% |
| 2016-03-31 | €476.25 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ono Pharmaceutical Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 74.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €790.91 Billion | 101.08% |
| Total Equity | €782.45 Billion | 100.00% |
Ono Pharmaceutical Co. Ltd Competitors by Market Cap
The table below lists competitors of Ono Pharmaceutical Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shin Kong Financial Holding Co Ltd
TW:2888
|
$6.58 Billion |
|
Laurus Labs Limited
NSE:LAURUSLABS
|
$6.59 Billion |
|
Terex Corporation
NYSE:TEX
|
$6.59 Billion |
|
Shenergy Co Ltd
SHG:600642
|
$6.59 Billion |
|
Kingfa Sci&Tech Co Ltd
SHG:600143
|
$6.57 Billion |
|
MYTILINEOS SA NAM.EO 097
F:MYH
|
$6.57 Billion |
|
SCREEN Holdings Co. Ltd
F:DAO
|
$6.55 Billion |
|
Informatica Inc
NYSE:INFA
|
$6.55 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ono Pharmaceutical Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 792,961,000,000 to 782,451,000,000, a change of -10,510,000,000 (-1.3%).
- Net income of 50,047,000,000 contributed positively to equity growth.
- Dividend payments of 37,516,000,000 reduced retained earnings.
- Share repurchases of 1,000,000 reduced equity.
- Other factors decreased equity by 23,040,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €50.05 Billion | +6.4% |
| Dividends Paid | €37.52 Billion | -4.79% |
| Share Repurchases | €1.00 Million | -0.0% |
| Other Changes | €-23.04 Billion | -2.94% |
| Total Change | €- | -1.33% |
Book Value vs Market Value Analysis
This analysis compares Ono Pharmaceutical Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | €979.42 | €13.27 | x |
| 2018-03-31 | €1019.97 | €13.27 | x |
| 2019-03-31 | €1084.08 | €13.27 | x |
| 2020-03-31 | €1126.95 | €13.27 | x |
| 2021-03-31 | €1273.28 | €13.27 | x |
| 2022-03-31 | €1343.40 | €13.27 | x |
| 2023-03-31 | €1519.18 | €13.27 | x |
| 2024-03-31 | €1688.42 | €13.27 | x |
| 2025-03-31 | €1665.59 | €13.27 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ono Pharmaceutical Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.40%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.28%
- • Asset Turnover: 0.46x
- • Equity Multiplier: 1.36x
- Recent ROE (6.40%) is below the historical average (10.74%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 5.30% | 15.58% | 0.30x | 1.15x | €-22.16 Billion |
| 2017 | 10.75% | 22.79% | 0.40x | 1.19x | €3.88 Billion |
| 2018 | 9.59% | 19.20% | 0.43x | 1.16x | €-2.15 Billion |
| 2019 | 9.25% | 17.86% | 0.44x | 1.18x | €-4.20 Billion |
| 2020 | 10.61% | 20.42% | 0.43x | 1.20x | €3.46 Billion |
| 2021 | 11.87% | 24.39% | 0.41x | 1.18x | €11.87 Billion |
| 2022 | 12.28% | 22.28% | 0.49x | 1.13x | €14.93 Billion |
| 2023 | 15.19% | 25.21% | 0.51x | 1.19x | €38.54 Billion |
| 2024 | 16.14% | 25.46% | 0.55x | 1.15x | €48.68 Billion |
| 2025 | 6.40% | 10.28% | 0.46x | 1.36x | €-28.20 Billion |
Industry Comparison
This section compares Ono Pharmaceutical Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $1,724,091,020,386
- Average return on equity (ROE) among peers: 10.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ono Pharmaceutical Co. Ltd (ON4) | €788.20 Billion | 5.30% | 0.35x | $6.58 Billion |
| Bayer Aktiengesellschaft (BAYA) | $32.05 Billion | -7.96% | 2.46x | $38.90 Billion |
| Bayer AG NA (BAYN) | $12.85 Billion | 13.19% | 3.35x | $45.18 Billion |
| Chugai Pharmaceutical Co., Ltd. (CUP0) | $2.03 Trillion | 21.42% | 0.22x | $76.91 Billion |
| CSPC Pharmaceutical Group Limited (CVG) | $12.87 Billion | 17.98% | 0.40x | $10.18 Billion |
| EH3 (EH3) | $552.10 Million | -10.71% | 0.51x | $258.63 Million |
| JCR Pharmaceuticals Co., Ltd. (JCR) | $56.48 Billion | 9.75% | 0.81x | $427.84 Million |
| PT Kalbe Farma Tbk (LCLA) | $10.94 Trillion | 18.32% | 0.25x | $2.15 Billion |
| Otsuka Holdings Co. Ltd (OS1) | $2.44 Trillion | 4.99% | 0.38x | $25.67 Billion |
| Recordati Industria Chimica e Farmaceutica S.p.A (RER1) | $1.69 Billion | 23.08% | 1.50x | $10.43 Billion |
About Ono Pharmaceutical Co. Ltd
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules f… Read more